ORC-13661

DB18903InvestigationalSmall molecule

ORC-13661 is under investigation in clinical trial NCT05730283 (Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin).

Formula / weight: C₁₈H₁₉ClN₄O₂S · 390.89 g/mol (avg)
Also known as: (1R,8S)-4-{[(4-chlorophenyl)carbamoyl]amino}-11-methyl-5-thia-11-azatricyclo[6.2.1.0<sup>2,6</sup>]undeca-2-(6),3-diene-3-carboxamide · (4R,6S)-2-[[[(4-Chlorophenyl)amino]carbonyl]amino]-4,5,6,7-tetrahydro-5-methyl-4,6-ethanothieno[3,2-c]pyridine-3-carboxamide · 4,6-Ethanothieno[3,2-c]pyridine-3-carboxamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4,5,6,7-tetrahydro-5-methyl-, (4R,6S)-
Code names: ORC-13661

Resolves to

Compound

Structure

InChIKeyDAHGONXBHYVOPI-NWDGAFQWSA-NSMILESCN1[C@H]2CC[C@@H]1C1=C(C2)SC(NC(=O)NC2=CC=C(Cl)C=C2)=C1C(N)=O

What you can answer from here — as of April 23, 2025

1Clinical trialPhase, status and sponsor resolved per trial

Which companies are running trials of ORC-13661, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.